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Introduction
Lung cancer is the leading cause of cancer-related mortality worldwide, with non-small-cell lung cancer (NSCLC) accounting for approximately 80-85% of all cases. Most patients with advanced NSCLC have poor prognosis, where the 5-year survival rate is <5% [1] . Checkpoints are specific molecules on T cells and antigen-presenting cells [2] , when tumor cell activation of the signaling pathways downregulates the T-cell immune response. In this context, checkpoint inhibitors are new, emerging, potential strategies in oncology, especially in advanced NSCLC. Ipilimumab is a monoclonal inhibitor antibody directed against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), a known checkpoint, that has shown exciting effects on melanoma and lung cancer [3] . Programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) may also demonstrate extensive antitumor activity [4, 5] . Nivolumab is a fully human immunoglobulin 4 (IgG4) PD-1 receptor inhibitor antibody that was approved in 2015 by the US Food and Drug Administration for treating melanoma, renal cell carcinoma, and NSCLC with durable response and tolerable toxicity. Besides, nivolumab reserves preferable option for classical Hodgkin's lymphoma, head and neck squamous cell carcinoma (HNSCC), and urothelial cancer [6] .
The pharmaceutical giant Bristol-Myers Squibb (BMS) provided the main sponsorship for producing this novel monoclonal antibody; however, many single-arm studies have reported the benefits and risks of nivolumab for treating NSCLC without control therapies, and the results reported were controversial. The small sample sizes were not adequately powered to detect the actual efficacy of nivolumab and might misestimate its performance in clinical practice. Hence, we systematically reviewed the current available literature to conduct the present single-arm metaanalysis with the aim of describing the general benefit and risk of nivolumab. The secondary objective was to evaluate whether the objective response rate (ORR) of nivolumab-treated patients with NSCLC with positive and negative PD-L1 expression is significantly different.
Materials and Methods
Our single-arm meta-analysis is accordance with PRISMA (Preferred Reporting Items for Systematic Review and Meta-Analysis) guidelines (Table S1 ) [7] and has been registered with PROSPERO (International Prospective Register of Systematic Reviews, CRD42017064411).
Search strategy
We systematically searched PubMed, the Cochrane Library, Embase, MEDLINE, and Web of Science from 1 January 2012 to 31 December 2017 without any language restrictions for noncomparative clinical studies and randomized controlled trials (RCTs). The combined text and medical subject heading (MeSH) terms used were as follows: "Carcinoma, Non-Small-Cell Lung" and "nivolumab." The complete search we used for PubMed was as follows: (Carcinoma, Non-Small-Cell Lung [ We also manually searched the reference lists of the retrieved literature for further eligible articles.
Selection criteria
We included studies that met the following criteria [8] :
(1) Adult patients with advanced NSCLC whose life expectancy was at least 3 months and without any autoimmune disease; Eastern Cooperative Oncology Group performance status was ≤2; there were no restrictions and no significant difference on sex, race, region, nationality, pretreatment; (2) Single-agent nivolumab or in combination with other chemotherapy drugs; (3) Whether comparison had been performed; (4) The main study outcome directly or indirectly included ORR, 1-year overall survival rate (1-yOS rate), progression-free survival rate at 24 weeks (PFS at 24 weeks rate), any-grade adverse effects rate (any-grade AEs%), and grade 3-4 adverse effects rate (grade 3-4 AEs%; treatment-related AE status was assessed using the Lung Cancer Symptom Scale and the European Quality of Life-5 Dimensions questionnaire [9] ); and (5) Noncomparative clinical studies (noncomparative openlabel studies) and RCTs.
The most complete and novel reports were included for data extraction and assessments if the objects were duplicated. We excluded reviews without original data, meta-analyses, and animal experiments.
Data extraction and quality assessment
Two investigators (W.X. Zhang and D.L. Yu) extracted the following information from each included study independently: first author, publication year, region, number of participants enrolled, participant characteristics, phase of clinical study, cohort completeness, tumor histology, clinical setting, endpoint, corresponding provided outcome, and study design. For noncomparative studies, we extracted total summarized data and subgroup figures or information if available; from the RCTs, we extracted data on clinical setting and outcome of intervention and control groups. The main outcomes were ORR, 1-yOS rate, PFS at 24 weeks rate, any-grade AEs%, and grade 3-4 AEs%. The other outcomes included median OS (mOS, months), median PFS (mPFS, months), median duration of response (mDOR, weeks), complete response rate (CR), partial response rate (PR), stable disease rate (SD), disease control rate (DCR), and ongoing response rate. All extracted information and original data were entered in standardized tables. Although not treated as a main outcome, we report the detailed AE conditions and PD-L1 biomarker status. Disagreements were resolved by a third investigator (Y.P. Wei).
We used the Cochrane risk of bias tool [10] to evaluate the quality of eligible RCTs. However, there are no textbook quality guidelines for noncomparative clinical studies, for which there is large heterogeneity, to date [11] . Therefore, we only assessed study quality via powered data volume and integrity, distinguished journals, and influential writers or teams who represented the leading position of NSCLC course and research.
Statistical analysis
For the included studies, we analyzed the main outcomes only concerning nivolumab specifically. We input the total B. Zhao et al. Single-Arm Meta-Analysis of Nivolumab in NSCLC clinical setting percentage for the main outcome and number of participants of each study, and then calculated the corresponding standard errors of these quasinormal distribution "rates" using Stata (StataCorp, USA). The 95% confidence lower interval (LI) and upper interval (UI) derived from the "rates" and standard errors could be justified. Lastly, the pooled effect sizes (ES), which denoted median "rates" and the 95% confidence intervals (95% CI), were output [12] . We also modified the final ES by omitting studies with large variability. Pooled ES aided the general evaluation of nivolumab benefit and risk. Heterogeneity across studies was examined by the Cochran Q chi-square test and the I 2 statistic. Studies with an I 2 statistic of 25-50%, 50-75%, and >75% were deemed to have low, moderate, and high heterogeneity, respectively [13] . P < 0.1 for the Q test was taken to indicate significant heterogeneity. We used random-effects models for all pooled ES because there was great subjectivity given the lack of related control groups in the noncomparative studies, and a tendency toward high heterogeneity [14] . Subgroup analyses were conducted according to study design, medication type, program subgroup, region, study phase, and histology. The subgroup analyses were performed only for modified ORR and grade 3-4 AEs% because of the abundant available data.
Relative risk (RR) and the random-effects model were used to estimate whether there was a significant difference in ORR between patients with positive and negative PD-L1 expression.
Potential publication bias among the main outcomes was assessed using the Egger linear regression test [15] . All analyses were performed using Stata statistical software version 12.0 (StataCorp, USA, https://www.stata.com); two-sided P < 0.05 was considered statistically significant except where otherwise specified.
Results

Study identification
Searching the above-mentioned databases yielded a total 754 records, and we obtained another 30 records from the reference lists and Google Scholar. We excluded 61 articles for duplication, 648 studies were excluded for next exclusion. The sequence order step and quantity of next exclusion was (1) 588 studies were excluded for no corresponding studies (n = 588), (2) review (n = 42), (3) animal experiment (n = 8), and (4) meta-analysis (n = 10). The remaining 45 studies were assessed through full-text revision, and 25 of them were excluded because of two reasons: first no nivolumab exposure (n = 12) and second no available outcome data (n = 13). The remaining 20 articles were eligible for quantitative synthesis. Figure 1 shows the selection process.
Study characteristics
The present single-arm meta-analysis included a total 20 studies [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] involving 3404 participants; Table 1 describes the main study characteristics, and Table 2 presents the outcome results. The studies were all published between 2012 and 2017. The sample sizes of each study ranged from 33 to 582 (of a total 3404, there were 2754 patients in the nivolumab group for main outcome calculation). Three studies [23, 24, 35] were randomized, open-label studies (CheckMate 017, CheckMate 057; CheckMate 026, unblinded), and 17 studies [16-22, 33, 34] were noncomparative, openlabel cohort studies. Nine studies [17-22, 26, 28, 30] were published abstracts, and eleven studies [16, 23-25, 27, 29, 31-35] were original studies. Three studies [29] [30] [31] had been performed in Europe; the remaining 17 [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [31] [32] [33] [34] [35] had been conducted in North America. Eight studies [16-19, 21, 25, 32, 33] set nivolumab subgroups based on dosage or cycle; six studies [17-19, 21, 32, 33] used nivolumab concurrently with chemotherapy drugs (platinum-based [17, 32] , ipilimumab [18, 19, 33] , bevacizumab [21] ). There were 10 phase I studies [16-19, 21, 22, 25, 31-33] , four phase II studies [20, 26, 27, 34] , and six phase III studies [23, 24, [28] [29] [30] 35] . Five studies [20, 24, 27, 28, 30] included patients with squamous NSCLC for clinical study; two studies [23, 34] involved patients with nonsquamous NSCLC; and 13 studies [16-19, 21, 22, 25, 26, 29, 31-33, 35] involved mixed histological types. Eight studies reported the ORR in positive and negative PD-L1 expression. All studies were published in English, and all enrolled patients had received prior relevant therapy.
Quality assessment
The three RCTs [23, 24, 35] were assessed using the Cochrane risk of bias tool and did not demonstrate allocation concealment and blinding methods, but generated random sequences, provided complete outcome data, reported no selective outcome, and were free of other bias (Table S2) . We included noncomparative studies from top journals or distinguished scientists, which ensured their high quality and integrity.
Main outcome
In 19 studies reporting ORR [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [30] [31] [32] [33] [34] [35] , the pooled ORR was 20% (95% CI: 16-24%) with high heterogeneity (I 2 = 87.3%, P < 0.001). After omitting six studies with large heterogeneity [21, 28, [32] [33] [34] [35] , the pooled ORR was 18% (95% CI: 15-20%) with low heterogeneity (I 2 = 20.6%, P = 0.235; Table 3 ).
Ten studies reported the 1-yOS rate [21, 23-25, 27, 29, 31, 32, 34, 35] ; the pooled 1-yOS rate was 55% (95% CI: 48-63%) with high heterogeneity (I 2 = 83.6%, P < 0.001). After omitting five studies with great heterogeneity [21, 31, 32, 34, 35] , the pooled 1-yOS rate was 45% (95% CI: 40-50%) with low heterogeneity (I 2 = 44.2%, P = 0.128; Table 4 ).
Six studies reported the PFS at 24 weeks rate [16, 18, 20, 31, 32, 35] ; the pooled PFS at 24 weeks rate was 37% (95% CI: 30-45%) with moderate heterogeneity (I 2 = 74.5%, P = 0.004). After omitting two studies with great heterogeneity [16, 20] , the pooled result was 42% (95% CI: 37-48%) with quite low heterogeneity (I 2 = 12.7%, P = 0.329; Table S3 ).
Fifteen studies reported the any-grade AEs% [19-25, 27, 29-35] ; the pooled result was 60% (95% CI: 46-75%) with high heterogeneity (I 2 = 98.0%, P < 0.001). After omitting two studies with tremendous heterogeneity [22, 32] , the pooled results were 61% (95% CI: 50-73%) with little reduction in heterogeneity (I 2 = 96.4%, P < 0.001; Table 5 ).
Eighteen studies reported grade 3-4 AEs% [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [29] [30] [31] [32] [33] [34] [35] ; the pooled grade 3-4 AEs% was 20% (95% CI: 15-25%) with high heterogeneity (I 2 = 93.4%, P < 0.001). After omitting five studies with extraordinary heterogeneity [17-19, 32, 33] , the pooled result was 12% (95% CI: 9-16%) with little reduction in heterogeneity (I 2 = 89.1%, P < 0.001; Table 6 ). Table S4 presents more details on the AEs%. Ipilimumab is a recombinant, fully human, monoclonal antibody targeted at cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) that is available for the treatment of advanced melanoma.
e Median age (range).
f
The same dosage and duration of nivolumab with different types of ipilimumab. 
Other outcomes
In view of the limitations of clinical meaning and statistical methodology, we elected not to pool the other outcomes.
Subgroup analysis
To determine whether the treatment effect of nivolumab was consistent across various subgroups, the between-group treatment effect for the modified ORR and grade 3-4 AEs% was estimated within each category of the following classification variables: study design (RCT, noncomparative open-label cohort study), medication (nivolumab, nivolumab with other drugs), program subgroup (no subgroup therapy, with subgroup therapy), region (North America, Europe), study phase (I, II, III), and histology (squamous, nonsquamous, mixed). Table 7 lists the subgroup analysis results. 
ORR in PD-L1 expression
Eight studies [16, 18, 20, 23, 24, 27, 31, 34] reported the pending relationship between ORR and PD-L1 expression systematically. An expression level of <5% was deemed PD-L1-negative, and ≥5% expression was deemed PD-L1-positive. RR with the random-effects model was used because its assumptions accounted for the presence of variability among the studies. ORR had significant associations with PD-L1-positive and PD-L1-negative expression (95% CI: 1.71-3.38, P < 0.001) with no heterogeneity (I 2 = 0, P = 0.541; Fig. 2 ). Specifically, there was no significant association between PD-L1 expression with mixed histology (95% CI: 0.89-5.14, P = 0.089) and squamous NSCLC (95% CI: 0.97-2.87, P = 0.066) with no heterogeneity (I 2 = 0, P = 0.369; I 2 = 0, P = 0.889; Fig. 3 ).
Publication bias diagnosis
The Egger regression test suggested bias in the ORR and grade 3-4 AEs% analysis and that the bias remained present in the grade 3-4 AEs% after studies of large variability had been removed. In fact, some deviations remained in the Egger test, as large heterogeneity across studies contributes to false positives in diagnosing publication bias [36] . Furthermore, most of the included clinical studies 
Discussion
From our manuscript we knew, nivolumab showed astonishing and persistent efficacy as well as manageable toxicity. The ORR was closely associated with PD-L1 expression in that positive PD-L1 expression resulted in a higher ORR. Most subgroups yielded results consistent with the overall outcome. There was pronounced ORR improvement in patients with nonsquamous NSCLC who had been treated with nivolumab plus ipilimumab; however, concurrent drug use might increase the potential risk of grade 3-4 AEs%. Generally, the RCTs reported better results than the noncomparative studies, and phase III clinical studies reported more precise indications. However, considerable heterogeneity across studies limited the actual efficacy and possibility of first-line chemotherapy with nivolumab. Our study is meaningful and has large impact on clinical practice especially in the patients with NSCLC immunotherapy treatment and management. Nivolumab has more beneficial response rate and overall survival than other second-line chemotherapy drugs (docetaxel), and less adverse effects (AEs) were detected in nivolumab group than in platinum-based group. All the efficacy and safety profile showed potential promotion of nivolumab. When comparing to other checkpoints (CTLA-4) inhibitor antibody, the final conclusion still keeps debatable and unclear; however, we found nivolumab plus ipilimumab improved the efficacy of single-agent nivolumab without significant AEs difference. Based on this finding, concurrent immunotherapy (such as nivolumab plus ipilimumab) might become standard strategy of crucial efficacy in oncology treatment. Furthermore, no evidence showed large exposure of nivolumab enhanced the overall survival of mixedhistology patients with NSCLC, and treatment-related AEs kept no significant as well. So according to cost-effective analyses, nivolumab of 3 mg/kg Q2W is now the wellaccepted adminstration methods. These meanings represent valuable priority for further studies and researches.
Inducing or potentiating immune responses via immunotherapeutic manipulation is a viable treatment approach in lung cancer. Currently, T-cell modulating agents are being investigated, where antibodies against CTLA-4, such as ipilimumab, exhibit great efficacy in treating NSCLC in combination with platinum-based chemotherapy [37] . PD-1 checkpoint blockade highlights the potential efficacy of the broad applicability of immunotherapy, and nivolumab, a BMS-sponsored human IgG4 monoclonal antibody, is the first approved immunotherapy drug for advanced squamous NSCLC [38] . Many reviews [6, [39] [40] [41] [42] and clinical studies have summarized the good tolerance and favorable clinical activity of nivolumab against a wide variety of malignancies, including NSCLC. Nivolumab can block the activated phosphatidylinositol 3-kinase (PI3K)/ AKT phosphatase SHP2 pathway that switches off T-cell and B-cell antitumor activity when PD-1 binds to PD-L1 [43, 44] . Some additional signaling pathway may also be involved in the inhibitor process. The encouraging efficacy can also be explained by the phenomenon that when PD-1 connects to PD-L1, coding somatic mutations create new epitopes or peptides identified by peripheral immune system to enhance antitumor immunity [45] [46] [47] [48] [49] . In the present meta-analysis, we found that patients with epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) translocation received additional tyrosine kinase inhibitor therapy, as EGFR and ALK mutations derive great benefit from nivolumab [50] . The included studies involved various dosages and cycles of nivolumab, but the actual benefit and risk remain unknown; some reports have stated that high-dose nivolumab may confer obvious benefit but with uncontrolled AEs [51] , but, on the contrary, some scientists insisted different nivolumab exposure was not associated with patients OS and toxicity [52] . The present metaanalysis shows that the most common AEs caused by nivolumab were fatigue and rash; there were few grade 3-4 AEs in the total AEs. We proved that PD-L1 expression predicted the efficacy of nivolumab treatment; in addition, high PD-L1 expression might inhibit tumor differentiation [53] .
Although our main outcome analysis on nivolumab treatment is biologically plausible, the results of the included individual studies were dissimilar, as reflected in the significant heterogeneity. Although we selectively removed studies of great variability, heterogeneity remained for any-grade AEs% and grade 3-4 AEs%. We also performed subgroup analysis, and there was no significant heterogeneity change in grade 3-4 AEs%. Besides study design, the clinical study phase, region, and some unidentified elements also confounded our final outcome.
Differing participant characteristics may cause inconsistent results, and nonuniform, patient-level EGFR mutation or ALK translocation could also have led to potential heterogeneity. Not all patients that required ALK inhibitor and EGFR tyrosine kinase inhibitor therapy received it, and most of the studies did not report the details of the administration of the target drugs.
Differing medication administration strategies may also have contributed to the heterogeneity. For example, highdose or long cycles of nivolumab may confer more benefit on patients with advanced NSCLC; the concurrent use of nivolumab with platinum-based drugs potentially increases grade 3-4 AEs%. There is no evidence that intravenous injection can help amplify nivolumab efficacy and reduce the AEs.
Methodologically, to a great extent, a single-arm metaanalysis is subject to subjectivity and heterogeneity. Furthermore, the measurement of outcome indicators differed greatly in the studies supported by BMS. Some negative results that would have affected the total efficacy of nivolumab might not have been reported. The lack of a standardized approach for assessing PD-L1 remained a limitation of the included studies.
Although there was inevitable heterogeneity in the included studies, our meta-analysis still has some strengths: We included more large-sample, high-quality studies, and our results are more convincing than those of Huang et al. [54] , who reported a small meta-analysis that omitted studies on different nivolumab dosages (except 3 mg/kg) and concurrent drug use. We found nivolumab not only demonstrated encouraging ORR but also exhibited durable response rate, longer PFS. More powerful evidence enhanced the beneficial profile of nivolumab and expanded future potential efficacy. However, limited by a few heterogeneity, we still warranted more highly described RCTs. In addition, the present meta-analysis systematically reviewed the latest published studies, included subgroups of different aspects, and reported the general any-grade AEs%. Nivolumab has demonstrated extensive activity both as a single agent and in combination with other drugs, and further exploration is worthwhile. PD-L1 can be a potential biomarker for predicting prognosis in NSCLC, but the benefit of nivolumab is greatly limited in patients with negative PD-L1 [55] . Does nivolumab still play a role in patients with advanced NSCLC with brain or bone metastasis?Whether we can find more surrogate checkpoint molecules expressed on resting or activation T cells, natural killers (NK) cells, etc., then reinforce these checkpoints as supplementary indicators for patients' prognosis and emerging tactics to treat refractory malignants [56] ? In addition, it will be important to establish the optimal timing of therapy and to determine whether immunotherapies are most effective when used alone or in combination with other agents. Promising results for immunotherapy have been reported, demonstrating CR and cures in patients with aggressive malignancies. The complex AEs and cost of engineering and administering of some forms of immunotherapy limit the use to a distinct patient population. Accordingly, high-throughput and cost-effective techniques are being used to broaden the applications of immunotherapy for treating cancer [42, 57] .
Our study still has some limitations. Initially, only two small studies reported results for nivolumab as compared with docetaxel; most of the included studies lacked control therapies. Due to the lack of terms of concrete control strategy, we only evaluated the efficacy and risk under subjectivity and selection bias without significantly statistical conclusions. Second, nonuniform patient level and trial level contributed to significant heterogeneity, and partial publication bias undermined the credibility of our results to an extent. However, most confounding factors were derived from methodology restrictions. Lastly, we could not extract sufficient details on the relationship between ORR and PD-L1 expression; more data are required to support the results of the 1-yOS rate and PFS at 24 weeks rate and to establish the assessments of other clinical endpoints such as the median OS, median PFS, CR, PR, and SD.
In summary, nivolumab has the potential to mount an ongoing, dynamic immune response for an extended period rather than a temporary killing of tumor cells after the pretarget therapy has been administered. The novel benefits and low risk of AEs enable nivolumab to emerge as a second-line chemotherapy drug, and with the use of other concurrent checkpoint antibodies, will form a 
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